Skip Navigation
  Search Menu
Find an Expert

 

Channing Judith Paller, M.D.

Photo of Dr. Channing Judith Paller, M.D.

Assistant Professor of Oncology

Female

Expertise: Bladder Cancer, Kidney Cancer, Medical Oncology, Prostate Cancer, Testicular Cancer, Urological Oncology

Research Interests: TGF-beta receptor inhibitor and tumor microenvironment; natural products including mistletoe, pomegranate, vitamin C, vitamin D, and muscadine grape skin extract; aurora kinase inhibition; phase I combination drug trial design ...read more

Request an Appointment

I live in Maryland

410-955-8964
Request an appointment through MyChart!

I live outside of Maryland

410-464-6641
Request Appointment

I live outside of the United States

+1-410-502-7683
Request Appointment

Locations

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Appointment Phone: 410-955-8964

401 N. Broadway
Harry and Jeanette Weinberg Building
Baltimore, MD 21231 map
Phone: 410-955-8893
Fax: 410-955-8587

Sibley Memorial Hospital
Appointment Phone: 202-660-6500

5255 Loughboro Road, NW
1st Floor
Washington, DC 20016 map
Fax: 202-660-6501

Contact for Research Inquiries

1650 Orleans Street
The Bunting Blaustein Cancer Research Building
Baltimore, MD 21231 map
Phone: 410-955-8239
Fax: 202-660-6501

Background

Dr. Channing J. Paller is a medical oncologist at Sibley Memorial Hospital and an assistant professor of oncology at the Johns Hopkins University School of Medicine. She is board certified in internal medicine and medical oncology and practices out of the Prostate Cancer Multidisciplinary Clinic at Sibley in Washington, D.C. and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, MD.

Dr. Paller has an expertise in prostate, bladder, kidney and testicular cancer.
 
Dr. Paller earned her medical degree from Harvard Medical School and completed a residency in internal medicine, followed by a fellowship in hematology and oncology at Johns Hopkins University School of Medicine. In addition, Dr. Paller completed a rotation with the chief of the Investigational Drug Branch at the National Cancer Institute (NCI) Cancer Therapy Evaluation Program and a rotation with the associate director for regulatory science in the Office of Oncology Drug Products at the Food and Drug Administration. She also completed rotations at the Weizmann Institute of Israel’s Department of Biological Regulation and McCord Hospital in South Africa, where she participated in the Harvard AIDS project.
 
In 2016, Dr. Paller was one of only five oncologists awarded the NCI Mentored Patient-Oriented Research Career Development Award. In 2015, she received the 2015 Passano Clinician Scientist Award for early stage research that is already making a contribution to science. Earlier in her career, she was selected for both a 2011-2012 Young Investigator Award by the American Society of Clinical Oncology and for the 2011-12 Eastern Cooperative Oncology Group Paul Carbone Award.

Dr. Paller is a member of the American Society of Clinical Oncology and the American Association for Cancer Research.
 
Dr. Paller’s research focuses on evaluating new therapies for prostate cancer, particularly combination therapies that engage the immune system. She is the principal investigator on two multi-site clinical trials and was the first author on the NCI Investigational Drug Steering Committee publication, “Consensus Recommendations on the Phase I Combination Clinical Trials of the Clinical Trial Design Task Force.” Dr. Paller was the chair for the oral abstract session on genitourinary cancer at the 2015 Annual Meeting of the American Society of Clinical Oncology and she is currently funded by an NCI immunotherapy grant to look at combination therapies that link standard of care therapy with inhibition of transforming growth factor beta in prostate cancer. She is also opening trials of vitamin C with chemotherapy in prostate cancer and of mistletoe in all solid tumors.

...read more

Titles

  • Assistant Professor of Oncology
  • Assistant Professor of Urology

Departments / Divisions

Education

Degrees

  • MD, Harvard Medical School (2005)

Residencies

  • Johns Hopkins University School of Medicine / Medicine (2008)

Fellowships

  • Johns Hopkins University School of Medicine / Hematology and Oncology (2012)

Board Certifications

  • American Board of Internal Medicine / Internal Medicine (2008)
  • American Board of Internal Medicine / Medical Oncology (2010)

Research & Publications

Research Summary

Dr. Paller’s research focuses on evaluating new therapies for prostate cancer, particularly combination therapies that engage the immune system.

Clinical Trials

Dr. Paller is the principal investigator on multi-site clinical trials and was the first author on the NCI Investigational Drug Steering Committee publication, “Consensus Recommendations on the Phase I Combination Clinical Trials of the Clinical Trial Design Task Force.”

Selected Publications

View all on Pubmed

Paller CJ, Ye X, Wozniak PJ, Gillespie BK, Sieber PR, Greengold RH, Stockton BR, Hertzman BL, Efros MD, Roper RP, Liker HR, Carducci MA. A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer. Prostate Cancer Prostatic Dis. 2013 Mar;16(1):50-5. doi: 10.1038/pcan.2012.20. Epub 2012 Jun 12. PMCID: PMC3549301.

Paller CJ, Olatoye D, Xie S, Zhou X, Denmeade SR, Eisenberger MA, Antonarakis ES, Carducci MA, Rosner GL. The effect of the frequency and duration of PSA measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer. Prostate Cancer Prostatic Dis. 2014 Mar;17(1):28-33. doi: 10.1038/pcan.2013.40. Epub 2013 Oct 8. PMCID: PMC3945997.

Paller, C., Bradbury, P.A., Ivy, P., Seymour, L., LoRusso, P., Baker, L., Rubinstein, L., Huang, E., Collyar, D., Groshen, S., Reeves, S., Ellis, L.M., Sargent, D., Rosner, G.L., LeBlanc, M., Ratain, M.J. The Design of Phase 1 Combination Trials: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee. Clinical Cancer Research. 2014, 20(16): 4210–4217. PMCID: PMC4135521.

Paller CJ, Kanaan YM, Beyene DA, Naab TJ, Copeland RL, Tsai HL, Kanarek NF, Hudson TS. Risk of Prostate Cancer in African American Men: Evidence of Mixed Effects of Dietary Quercetin by Serum Vitamin D Status. Prostate. 2015 Sep;75(13):1376-83. PMCID: NIHMS689470.

Activities & Honors

Honors

  • Passano Clinician Scientist Award, 2015
  • Young Investigator Award, American Society of Clinical Oncology, 2011 - 2012
  • Paul Carbone Award, Eastern Cooperative Oncology Group, 2011 - 2012
  • NCI Mentored Patient-Oriented Research Career Development Award, National Cancer Institute, 2016

Memberships

  • American Society of Clinical Oncology (ASCO)

    2015 Chair for the Oral Abstract Session on Genitourinary Cancer at ASCO's Annual Meeting

  • American Association for Cancer Research

Videos & Media

Recent News Articles and Media Coverage

Six Cutting Edge Medical Procedures Happening in the Bethesda Area. Bethesda Magazine (November/December, 2016)

Some D.C. Doctors Are Tackling Cancer Cures in a Surprisingly Low-Tech Way. Washington Business Journal (09/29/2016)

Isn’t It Time We Acknowledged the Potential of Immunotherapy? The Telegraph (05/26/2015)

How Mistletoe Became Everyone’s Favorite Parasite. National Geographic (12/18/2015)

Is this you? Edit Profile